摘要
目的分析乳腺癌患者外周血中髓样抑制细胞（MDSCs）水平，鉴定乳腺癌特异性MDSCs的生物学特征并评估其临床意义。方法抽取乳腺癌患者（84例）、乳腺良性肿瘤患者（37例）和健康体检者（21例）静脉血2ml，其中乳腺癌患者采血时间为新辅助治疗前后或手术治疗前后。采用流式细胞术，通过抗CD11b、CD33、CD14和HLA—DR等荧光抗体鉴定受检者外周血中MDSCs的表面标志，并分析MDSCs水平与乳腺癌患者临床病理特征的关系。采用体外分离和细胞增殖实验检测MDSCs对T细胞功能的影响。结果乳腺癌患者外周血中存在MDSCs，其特征性细胞表面标志为CD11b＋CD33＋CD14-，CD11b＋CD33＋CD14-细胞在组织形态上属于单个核细胞。体外实验显示，CD11b’CD33’CD14-细胞能抑制T细胞增殖。乳腺癌组、乳腺良性肿瘤组和健康体检组患者外周血中MDSCs水平分别为（15．93±3．17）％、（8．92±4．42）％和（5．02±2．75）％，乳腺癌组患者外周血中MDSCs水平显著高于乳腺良性肿瘤组和健康体检组，差异有统计学意义（P〈0．001）。乳腺癌患者外周血中MDSCs水平与手术治疗有关，而与患者年龄、肿瘤分期、淋巴结转移、雌激素受体、孕激素受体表达无关。早期乳腺癌患者手术前后的MDSCs水平分别为（15．37±2．49）％和（7．83±3．78）％，差异有统计学意义（P〈0．001）。结论乳腺癌患者外周血中存在具有疾病特征性的MDSCs。CD11b＋CD33＋CD14-MDSCs与乳腺癌的发生和发展有关，可以作为一种新的生物标志物用于辅助诊断乳腺癌，并预测乳腺癌的转归。
Objective To investigate the presence, biological features, and clinical significance of myeloid-derived suppressor cells （MDSCs） in breast cancer patients. Methods Eighty-four cases of breast cancer, 37 cases of benign breast tumor and 21 cases of healthy individuals were included in this study. Samples of peripheral blood （2 ml） were collected, and in the breast cancer patients, blood samples were taken both before and after treatment. Flow cytometry using anti-CDllb, CD33, CD14 and HLA-DR antibody was conducted to identify the unique membrane markers of MDSCs, and statistical analysis was performed to explore the relationship between MDSCs and clinical factors. Cell isolation and in vitro assay were used to test T cell function. Results CDllb＋CD33＋CD14- MDSCs were present in the blood of breast cancer patients, and these MDSCs were histologically of mononuclear cells. Cell proliferation assay confirmed that MDSCs inhibited proliferation of homologous T cells in vitro. MDSCs levels in patients with breast cancer, benign disease and the health control were （15.93±3.17） %, （8.92±4.42）% and （5.02±2.75） %, respectively, with a statistically significant difference （P〈0.001） between breast cancer patients and the other subjects （ patients with benign lesions and healthy controls）. The expression level of MDSCs in patients with breast cancer was associated with surgical treatment, but not with age, disease stage, lymph node metastasis, ER or PR expression. MDSCs levels were significantly lower in post-operative patients [ （7.83 ± 3.78） %] than the （15.37±2.49） % in patients before surgery （P〈0.001）. Conclusions The results of this study demonstrate that MDSCs are present in the peripheral blood of breast cancer patients and the level of MDSCs is associated with surgical treatment. Our findings suggest that CD11b＋CD33＋CD14- MDSCs are likely involved in breast cancer initiation and development, and may become a novel biomarker to facilitate diagnosis and to predi
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2016年第2期118-123,共6页
Chinese Journal of Oncology
基金
吉林省自然科学基金（201115216）
关键词
乳腺肿瘤
髓样抑制细胞
诊断
治疗
Breast neoplasms
Myeloid-derived suppressor cells
Diagnosis
Therapy
